| Literature DB >> 35632644 |
Olga V Morozova1,2,3, Valentin A Manuvera1,4,5, Alexander E Grishchechkin2, Nikolay A Barinov1,3, Nataliya V Shevlyagina2, Vladimir G Zhukhovitsky2, Vassili N Lazarev1,4,5, Dmitry V Klinov1,3,5.
Abstract
Background: Nanosilver possesses antiviral, antibacterial, anti-inflammatory, anti-angiogenesis, antiplatelet, and anticancer properties. The development of disinfectants, inactivated vaccines, and combined etiotropic and immunomodulation therapy against respiratory viral infections, including COVID-19, remains urgent. Aim: Our goal was to determine the SARS-CoV-2 molecular targets (genomic RNA and the structural virion proteins S and N) for silver-containing nanomaterials.Entities:
Keywords: ELISA; RNA-containing bacteriophage MS2; RT2-PCR; beta-coronavirus; nanosilver; xMAP
Mesh:
Substances:
Year: 2022 PMID: 35632644 PMCID: PMC9144282 DOI: 10.3390/v14050902
Source DB: PubMed Journal: Viruses ISSN: 1999-4915 Impact factor: 5.818
Figure 1TEM images with size ranges for Ag NCs with IgG, citrate coated Ag NPs and nanoconjugates of Ag NPs with IgG.
Figure 2AFM images and height distribution histograms of Ag-2S and Ag NCs with IgG.
Cytotoxic concentrations (CC50, μg/mL) of Ag-containing materials for human cell lines.
| Ag Nanomaterials | HEp-2 | L41 | HT-29 |
|---|---|---|---|
| AgNO3 | 50 (31.75 Ag+) * | 100 (63.49 Ag+) | 100 (63.49 Ag+) |
| Ag-2S | 5.3 (1.08 Ag+) | 21.2 (4.32 Ag+) | 15.9 (3.24 Ag+) |
| Ag NCs-IgG | 7 | 10 | 7 |
| nanoconjugates | 5 | 15 | 5 |
Note: * CC50 (concentration that caused 50% cytotoxicity of eukaryotic cells) is shown as concentration of the studied substances AgNO3 (MW = 169.87), Ag-2S (MW = 530.05) and corresponding concentrations of Ag+ are in brackets. For Ag NCs-IgG CC50 for protein were 1 mg/mL and 10 mg/mL for HEp-2(HT-29) and L41 cell lines, respectively and CC50 (by metal content) for Ag NCs was calculated from protein CC50 on the base of preliminary mass spectroscopy data. For Ag NPs-IgG silver concentration was determined on the base of atomic absorption spectroscopy (AAS) after preliminary treatment of the nanocongugate with HNO3.
Figure 3Scheme of SARS-CoV-2 molecular targets and part of available data of RT2-PCR and ELISA. SARS-CoV-2 spike surface protein S is shown in pink in both central virion scheme and in the corresponding ELISA data (the histogram in the upper right corner); the coronavirus nucleocapside protein N is shown in blue colour in the central scheme and in the corresponding ELISA data (the histogram in the lower right corner). RT2-PCR data demonstrate the fluorescent curves of dependence between PCR cycles (axis X with threshold cycle (Ct)) and the fluorescence emission in relative fluorescence units (r.f.u.).
Comparison of RNase activity of the silver nanomaterials at equal concentrations 0.1 mg/mL using RT2-PCR.
| Nanosilver | MS2 RNA | MS2 Phage | SARS-CoV-2 RNA | SARS-CoV-2 RNA from COVID-19 Patient Blood |
|---|---|---|---|---|
|
| n/d * | 2.0 ** | 0.9 | 0 *** |
|
| n/d | 7.5 | n/d | 1.6 |
|
| 0 | 0 | 0 | 0 |
|
| 3.7 | 0.9 | 1.8 | 0 |
|
| 3.7 | 0 | 1.3 | 0 |
|
| 0 | 0 | 0 | 0 |
Notes: * n/d means that targeted RNA was not detected because of complete cleavage. ** average shift of threshold cycles of fluorescence (Ct) between sample after treatment with silver-containing materials and control untreated sample (ΔCt = Ct (sample) − Ct (control)). *** “O” corresponds to insignificant Ct shift <1 compared to control sample in the presence of sterile water.
Figure 4ELISA results for SARS-CoV-2 recombinant antigen N after incubation with AgNO3, Ag NPs, Ag NPs-IgG, Ag NCs-IgG and Ag-2S.
Figure 5ELISA data for SARS-CoV-2 recombinant antigens N and S2 after their preliminary treatment with different concentrations of AgNO3 and Ag NPs.
Unknown (X) Multi Analyte Profiling (xMAP) results for 17 inflammation biomarkers in HEp-2 cells in 2 days posttreatment. Normalization was carried out as a ratio of mean fluorescence intensity (MFI) for wells after incubation with the nanosilver to MFI of control intact HEp-2 cells.
| Th1 | Th2 | Th17 | Others | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Inflammation Biomarkers | IFNγ | TNFα | IL-1β | IL-12(p70) | IL-2 | IL-4 | IL-5 | IL-6 | IL-7 | IL-8 | IL-10 | IL-13 | IL-17A | G-CSF | GM-CSF | MCP-1 (MCAP) | MIP-1β |
|
| 1.03 | 1.15 ↑ | 1.38 ↑ | 0.70 | 0.74 | 0.84 | 0.88 | 0.85 | 0.70 | 3.71 ↑ | 0.78 | 0.81 | 0.97 | 1.12 ↑ | 0.92 | 1.19 ↑ | 1.17 ↑ |
|
| 0.93 | 0.78 | 0.63 | 0.82 | 0.54 | 0.78 | 0.83 | 1.05 | 0.91 | 0.93 | 0.79 | 0.95 | 0.62 | 0.76 | 0.88 | 0.94 | 0.68 |
|
| 0.76 | 0.72 | 0.70 | 0.70 | 0.82 | 0.74 | 0.70 | 0.75 | 0.50 | 0.64 | 0.78 | 0.69 | 0.76 | 0.78 | 0.79 | 0.85 | 0.76 |
|
| 0.72 | 0.65 | 1.00 | 0.72 | 0.78 | 0.75 | 0.82 | 0.75 | 0.55 | 1.00 | 0.77 | 0.83 | 0.84 | 1.00 | 0.83 | 1.15 ↑ | 0.97 |
|
| 0.68 | 0.51 | 2.11 ↑ | 0.54 | 0.48 | 0.43 | 0.60 | 0.41 | 0.44 | 0.34 | 0.54 | 0.50 | 0.97 | 1.20 ↑ | 0.83 | 0.76 | 0.66 |
Note: * Ag NCs with red fluorescence (excitation at 340–540 nm; fluorescence emission maximum at 650 nm) (Supplementary Data Figure S2).